Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health.
Addictive behaviors June 1, 2026 Sebastian Ehmann, Nathan M Hager, Paul S Regier et al.
Using data from the 2023 U.S. National Survey on Drug Use and Health, lifetime use of mescaline or peyote was associated with lower opioid use disorder severity, while lifetime use of LSD, psilocybin, MDMA, or DMT was associated with higher severity. The link between mescaline/peyote use and lower severity appeared only among adults with high mental health impairment. The findings suggest that different types of psychedelic use have divergent relationships with opioid use disorder severity, and that mental health status may influence these associations.